6.76
+5.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arvinas
From its filings with the US Securities and Exchange Commission
Arvinas is based in New Haven, Connecticut and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ARVN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $262.6m and a net loss of $80.8m. At that date it held total assets of $717.9m and shareholders' equity of $433.9m.
We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. We believe that our targeted protein degradation approach is a novel therapeutic modality that may provide distinct advantages over existing therapies and address a broad range of targets, including historically undruggable proteins, in areas of significant unmet need.
In the past five years, seven of the programs developed using our PROTAC protein degradation platform have progressed to clinical trials in oncology and neurology indications after demonstrating potent and selective protein degradation in our preclinical studies. The U.S.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Sept 2018
- Employees
- 246
- Website
- arvinas.com ↗
- Head office
- 395 WINCHESTER AVE, NEW HAVEN, CT, 06511
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. John HoustonChairman of the Board, President, Chief Executive Officer, since 2017$12.7m
- Mr. Andrew SaikChief Financial Officer, Treasurer$3.5m
- Dr. Angela CacaceChief Scientific Officer$3.0m
- Dr. Noah BerkowitzChief Medical Officer$6.0m
- Dr. Briggs MorrisonLead Independent Director$480,385
- Dr. Sunil AgarwalIndependent Director$463,118
- Ms. Linda BainIndependent Director$461,525
- Mr. Everett CunninghamIndependent Director$453,565
- Mr. Edward KennedyIndependent Director$451,525
- Ms. Leslie NorwalkIndependent Director$451,525
- Dr. Laurie Smaldone AlsupIndependent Director$456,525
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 60
- Social
- 71
- Governance
- 41
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arvinas Inc has numerous strengths that contribute to its position as a leading company in the biotechnology industry. One of its key strengths is its innovative approach to targeting and degrading disease-causing proteins, which sets it apart from traditional therapies that merely inhibit protein function. This unique and groundbreaking technology gives Arvinas a competitive edge over its peers.
- The company has an impressive portfolio of drug candidates targeting various diseases, including some with high unmet medical needs. This diversified pipeline reduces the risk associated with a single product focus and provides potential for revenue growth across multiple therapeutic areas.
- Arvinas Inc also benefits from its strategic collaborations with major pharmaceutical companies, which provide access to additional resources, expertise, and potential partnership opportunities. These collaborations validate Arvinas' technology platform and enhance its overall credibility in the industry.
Weaknesses
- Despite its strengths, Arvinas Inc faces certain weaknesses that could hinder its growth and success. One of the main challenges is that the company's protein degradation technology is still in early stages of development. This means there are uncertainties and risks associated with clinical development, regulatory approvals, and commercialization, which could impact the company's ability to deliver on its promises.
- Additionally, as a relatively small biotech company, Arvinas Inc may face resource constraints compared to larger industry players. Limited financial capabilities and resources could limit the speed at which the company can advance its pipeline, execute on its business strategy, and compete effectively in the market.
Opportunities
- Arvinas Inc operates in an industry with significant growth prospects. The increasing prevalence of complex diseases and the need for more effective therapies present ample opportunities for the company to address unmet medical needs and capture a larger market share.
- Moreover, the expansion of strategic collaborations and partnerships can bring additional resources, funding, and expertise to Arvinas, which can help accelerate the development and commercialization of its drug candidates. The company can leverage these opportunities to further establish itself as a dominant player in the biotechnology space.
Threats
- Arvinas Inc faces several threats that could impede its growth and success. One major threat is the intense competition within the biotechnology industry. The presence of numerous established biotech companies, as well as new entrants, increases competitive pressures and the risk of market saturation. Arvinas must continuously innovate, differentiate its products, and demonstrate superior clinical efficacy to stay ahead of the competition.
- Additionally, regulatory and reimbursement challenges pose a threat to Arvinas' ability to bring its products to market and realize significant revenue. Stringent regulations, pricing pressures, and changes in healthcare policies can impact the company's ability to secure favorable market access and generate substantial sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.